Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

About Gene Salkind

Gene Salkind is an angel investor.

Gene Salkind Headquarters Location

California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Gene Salkind News

Prominent Biotech investor Gene Salkind adds another $2 M investment in CURE Pharmaceutical

Dec 5, 2018

Source: CBNB 2018/12/05 Source: Company press release, 1 Nov 2018 , 1 Nov 2018 , Website: http://www.globenewswire.com CURE Pharmaceutical, an innovative drug delivery and development company, has secured a $2 M investment at $2.5/share from Gene Salkind, a company advisor and biotech investor, bringing his total investment in the company to $3 M. In Feb 2018, Dr Salkind joined CURE's advisory board to help advance CURE's pipeline for the central nervous system and other therapeutic areas. Found on website: http://www.globenewswire.com. Released to ICIS 5 Dec 2018[This article was prepared by Chemical Business NewsBase (CBNB), a third party premium option available through ICIS news. For any queries about the content please contact: John Godfrey, godfreyj@elsevier.com, +44 (0) 1223 463167] SHARE THIS STORY

Gene Salkind Investments

2 Investments

Gene Salkind has made 2 investments. Their latest investment was in DermTech International as part of their Series B on August 8, 2013.

CBI Logo

Gene Salkind Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/20/2013

Series B

DermTech International

$5.6M

No

2

3/21/2008

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/20/2013

3/21/2008

Round

Series B

Series A

Company

DermTech International

Subscribe to see more

Amount

$5.6M

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

2

10

Gene Salkind Portfolio Exits

1 Portfolio Exit

Gene Salkind has 1 portfolio exit. Their latest portfolio exit was DermTech International on August 30, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/30/2019

Reverse Merger

$99M

3

Date

8/30/2019

Exit

Reverse Merger

Companies

Valuation

$99M

Acquirer

Sources

3

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.